Editas Medicine, Inc. (NASDAQ:EDIT) in recent session today was buoying at a rise of 13.39% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $32.49 and 5Y monthly beta was reading 2.01 with its price kept floating in the range of $36.51 and $39.95 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that EDIT hit a high price of $36.78 and saw its price falling to a low level of $14.01 during that period. Over a period of past 1-month, stock came adding 0.99% in its value.
With its current market valuation of $2.08 Billion, Editas Medicine, Inc. is set to declare its quarterly results on August 06, 2020. EDIT Stock’s Forward Dividend of 0 and its yield of 0 are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.79 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving down to -$3.06 for 2020 with estimates of that growing to -$3.18 in next year. These estimates are suggesting current year growth of 0.14% for EPS and 0.04% growth next year.
In contrast, when we review EDIT stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.
According to ratings assigned by 11 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 5 of them are recommending Editas Medicine, Inc. (EDIT) as a Hold, while 5 are in view that stock is a Buy. Recommendation by 1 analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
In comparing Editas Medicine, Inc. (EDIT)’s stock with other industry players reveals that stock’s latest price change of +13.39% and that of +31.91% over the past 12 months is in better position with that of Amgen Inc (AMGN) which saw its stock price fell by -0.67% in the recent trading and went through an increase of 30.91% in past 12-month trading. Industry’s another major player Bristol-Myers Squibb Company (BMY) has jumped 3.22% up in latest trading session, but over the past year has faced a rise of 30.64%, while Gilead Sciences Inc (GILD) is also up 13.39% however its price remained floating in the green at 31.91% over the same period. Editas Medicine, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 19.73 while Bristol-Myers Squibb Company is showing 73.78 for the same. On the other hand, the S&P 500 Index was down -0.16% in the early deals while the Dow Jones Industrial was dealing higher at 0.02%.
Having a second look at Editas Medicine, Inc. (NASDAQ:EDIT) provides that stock’s average daily trading volume for 3 months was 1.08 Million, while it jumped to 742.38 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock currently stood at 62.13 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 2.41% while it is 75.78% for the institutional holders. The figures also indicate that as of July 14, 2020, number of stock’s short shares was 8870000 which implies a short ratio of 5.85. This shows up a 14.27% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short declined as it was 9.08 Million in the previous month. Addition of +9.73% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.